Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia.

NCT ID: NCT05860595

Last Updated: 2025-08-05

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 3 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-05-23
• Study Completion Date: 2025-10-24

Brief Summary

This is a non-randomized, open-label, single-dose study. The aim of this study is to evaluate the safety and efficacy of the treatment with lentiviral vector encoding βA-T87Q-globin gene transduced autologous hematopoietic stem cells in subjects with transfusion-dependent β-thalassemia.

Detailed Description

Subject participation for this study will be 24 months. Subjects who enroll in this study will be asked to participate in a subsequent 13-year follow-up for gene therapy products.

Conditions

Transfusion-dependent Beta-Thalassemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

KL003 cell injection Drug Product

Each recruited subject will accept KL003 Transplantation.

Group Type: EXPERIMENTAL

KL003 cell injection Drug Product

Intervention Type: GENETIC

Transplant of auto-HSC transduced with lentiviral vector encoding βA-T87Q-globin gene.

Interventions

KL003 cell injection Drug Product

Transplant of auto-HSC transduced with lentiviral vector encoding βA-T87Q-globin gene.

Intervention Type: GENETIC

Eligibility Criteria

Inclusion Criteria

• Male or female age between 3-35 years
• Diagnosis of transfusion-dependent β-thalassemia and a history of at least 100 mL/kg/year of pRBCs or ≥8 transfusions of pRBCs per year for the prior 2 years
• Documented baseline, or pretransfusion, Hb level≤7 g/dL
• Karnofsky performance status ≥70 for subjects≥16 years of age; Lansky performance status of ≥70 for subjects<16 years of age
• Eligible to undergo auto-HSCT
• Willing and able to follow the research procedures and conditions, with good compliance
• Willing to receive at least the 2 years follow-up and maintain detailed medical records, including transfusion history
• Subject and/or legal guardians voluntarily participated in this clinical trial and signed the informed consent form, and can complete all follow-up in accordance with the protocol requirements

Exclusion Criteria

• Subjects positive with the following etiological tests: human immunodeficiency virus(HIV-1-2), human cytomegalovirus (HCMV-DNA), EB virus (EBV-DNA), HBV (HBsAg/HBV-DNA positive), HCV antibody (HCV-Ab), Treponema pallidum antibody (TP-Ab)
• Clinically significant and active bacterial, viral, fungal, or parasitic infection as determined by the clinical investigator
• Contraindication to bone marrow collection
• Any prior or current malignancy or myeloproliferative or significant immunodeficiency disorder
• A white blood cell (WBC) count <3×10^9/L, and/or platelet count <100×10^9/L not related to hypersplenism
• Diagnosis of composite α thalassemia
• Participants with severe iron overload at the time of screening: severe iron overload of the liver showed by MRI, serum ferritin ≥ 5000 ng/mL, or moderate to severe iron overload of the heart
• Presence of unusual antibody of red blood cell antigens or tested positive for platelet antibody
• Meet the criteria for allo-HSCT and with an identified willing donor with a full HLA match
• Prior receipt of gene therapy or allo-HSCT
• Immediate family member (i.e. parent or siblings) with a known Familial Cancer Syndrome (including but not limited to hereditary breast and ovarian cancer syndrome, hereditary non-polyposis colorectal cancer syndrome and familial adenomatous polyposis)
• Diagnosis of a significant psychiatric disorder of the subject that could seriously impede the ability to participate in the study
• History of major organ damage including:

1. Liver function test suggest AST or ALT levels >3× upper limit of normal (ULN);

2. Total serum bilirubin value >2.5×ULN;if combined with Gilbert syndrome, total bilirubin >3×ULN and direct bilirubin value >2.5×ULN;

3. History of bridging fibrosis, cirrhosis;

4. Left ventricular ejection fraction <45%;

5. New York Heart Association (NYHA) class III or IV congestive heart failure;

6. Severe arrhythmia requiring medical treatment;

7. Uncontrolled hypertension or unstable angina pectoris;

8. Myocardial infarction or bypass or stent surgery within 12 months before drug administration;

9. Valvular disease with clinical significance;

10. Baseline calculated eGFR<60mL/min/1.73m2;

11. Pulmonary function: FEV1/FVC<60% and/or diffusion capacity of carbon monoxide (DLco) <60% of prediction;

12. Evidence of clinically significant pulmonary hypertension requiring medical intervention.

• Uncorrectable coagulation dysfunction or history of severe bleeding disorder
• Any other condition that would render the subject ineligible for HSCT, as determined by the attending transplant physician
• Known allergy to clinical trial drug (plerixafor or G-CSF or busulfan) or ingredient(DMSO etc.)
• Participation in another clinical study with an investigational drug within 30 days of Screening or participating in another clinical study with an investigational drug
• Inoculated live vaccine within 6 weeks prior to screening
• Pregnancy or breastfeeding women; Subjects or their sexual partners were unable to take medically recognized effective contraceptive measures during the 27-month study period
• The subjects or their parents would not comply with the study procedures outlined in the protocol
• Receipt of hydroxyurea therapy within 3 months before HSCT harvest
• Patients considered to be ineligible for the study by the investigator for reasons other than the above

• Minimum Eligible Age: 3 Years
• Maximum Eligible Age: 35 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

R&D Kanglin Biotech

OTHER

Sponsor Role: collaborator

Institute of Hematology & Blood Diseases Hospital, China

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Regenerative Medicine Center

Tianjin, Tianjin Municipality, China

Countries

China

Other Identifiers

IIT2023021

Identifier Type: -

Identifier Source: org_study_id